1 |
Preston DC, Shapiro BE. Electromyography and neuromuscular disorders: clinical-electrophysiologic correlations. 3rd ed. Oxford: Sauders; 2012.
|
2 |
Karakis I, Liew W, Darras BT, Jones HR, Kang PB. Referral and diagnostic trends in pediatric electromyography in the molecular era. Muscle Nerve 2014;50:244-9.
DOI
|
3 |
Rabie M, Jossiphov J, Nevo Y. Electromyography (EMG) accuracy compared to muscle biopsy in childhood. J Child Neurol 2007;22:803-8.
DOI
|
4 |
Dubowitz V, Sewry CA, Oldfors A, Lane RJM. Muscle biopsy: a practical approach. 4th ed. Philadelphia: Saunders Elsevier; 2013.
|
5 |
Chae JH, Vasta V, Cho A, Lim BC, Zhang Q, Eun SH, et al. Utility of next generation sequencing in genetic diagnosis of early onset neuromuscular disorders. J Med Genet 2015;32:208-16.
|
6 |
Lim BC, Ki CS, Kim JW, Cho A, Kim MJ, Hwang H, et al. Fukutin mutations in congenital muscular dystrophies with defective glycosylation of dystroglycan in Korea. Neuromuscul Disord 2010;20:524-30.
DOI
|
7 |
Zvaritch E, Kraeva N, Bobardier E, McCloy RA, Depreux F, Holmyard D, et al. Ca2+ dysregulation in Ryr1 (I4895T/wt) mice causes congenital myopathy with progressive formation of minicores, cores, and nemaline rods. Proc Natl Acad Sci U S A 2009;106:21813-8.
DOI
|
8 |
Al-Ghamdi F, Darras BT, Ghosh PS. Spectrum of neuromuscular disorders with hyperCKemia from a tertiary care pediatric neuromuscular center. J Child Neurol 2018;33:389-96.
DOI
|
9 |
Kley RA, Shimidt-Wilcke T, Vorgerd M. Differential diagnosis of hyper-CKemia. Neurol Intern Open 2018;2:E72-83.
DOI
|
10 |
North KN. Clinical approach to the diagnosis of congenital myopathies. Semin Pediatr Neurol 2011;18:216-20.
DOI
|
11 |
Bohm J, Vasli N, Malfatti E, Le Gras S, Feger C, Jost B, et al. An integrated diagnosis strategy for congenital myopathies. PLoS One 2013; 8:e67527.
DOI
|
12 |
Bonnemann CG, Wang CH, Quijano-Roy S, Deconinck N, Bertini E, Ferreiro A, et al. Diagnostic approach to the congenital muscular dystrophies. Neuromuscl Disord 2014;24:289-311.
DOI
|
13 |
Eun BL, Kim SW, Kim YK, Kim JW, Moon JS, Park SK, et al. Introduction of national health screening program for infant and children. J Korean Child Neurol Soc 2007;15:142-7.
|
14 |
Sul YA, Yum MS, Lee YJ, Kim EH, Ko TS, Yoo HW. Floppy infant syndrome: clinical analysis and diagnositc approaches (2008-2012). J Korean Child Neurol Soc 2014;22:143-8.
DOI
|
15 |
Richer LP, Shevell MI, Miller SP. Diagnostic profile of neonatal hypotonia: an 11-year study. Pediatr Neurol 2001;25:32-7.
DOI
|
16 |
Paro-Panjan D, Neubauer D. Congenital hypotonia: is there an algorithm? J Child Neurol 2004;19:439-42.
DOI
|
17 |
Talbot K, Tizzano EF. The clinical landscape for SMA in a new therapeutic era. Gene Ther 2017;24:529-33.
DOI
|
18 |
Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, De Vivo DC, et al. Results from a phase 1 study of nusinersen (ISISSMN( Rx)) in children with spinal muscular atrophy. Neurology 2016; 86:890-7.
DOI
|
19 |
Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 2016;388: 3017-26.
DOI
|
20 |
Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus sham control in later-onset spinal muscular atropphy. N Engl J Med 2018;378:625-35.
DOI
|
21 |
McDonald CM, Henricon EK, Abresch RT, Duong T, Joyce NC, Hu F, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet 2018;391:451-61.
DOI
|
22 |
McDonald CM, Gordish-Dressman H, Henricson EK, Duong T, Joyce NC, Jhawar S, et al. Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: long-term natural history with and without glucocorticoids. Neuromuscul Disord 2018; 28:897-909.
DOI
|
23 |
Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol 2016;79:257-71.
DOI
|
24 |
Charleston JS, Schenell FJ, Dworzak J, Donoqhue C, Lewis S, Chen L, et al. Eteplirsen treatment for Duchenne muscular dystrophy: exon skipping and dystrophin production. Neurology 2018;90:e2146-54.
DOI
|
25 |
Voit T, Topaloglu H, Straub V, Muntoni F, Deconinck N, Champion G, et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomized, placebo-controlled phase 2 study. Lancet Neurol 2014;13:987-96.
DOI
|
26 |
Goemans NM, Tulinius M, van den Hauwe M, Kroksmark AK, Buyse G, Wilson RJ, et al. Long-term efficacy, safety, and pharmacokinetics of drisapersen in Duchenne muscular dystrophy: results from an openlabel extension study. PLoS One 2016;11:e0161955.
DOI
|
27 |
McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomized, doubleblind, placebo-controlled, phase 3 trial. Lancet 2017;390:1489-98.
DOI
|
28 |
Ho G, Carey KA, Cardamone M, Farrar MA. Myotonic dystrophy type 1: clinical manifestations in children and adolescents. Arch Dis Child 2018, in press.
|
29 |
Darras BT, Jones HR Jr, Ryan MM, De Vivo DC. Neuromuscular disorders of infancy, childhood, and adeloscence: a clinician's approach. 2nd ed. San Diego: Academic Press; 2014.
|
30 |
Goebel HH, Sewry CA, Weller RO. Muscle disease: pathology and genetics. 2nd ed. Chichester: Wiley-Blackwell; 2013.
|
31 |
Pina-Garza JE, Fenichel GM. Fenichel's clinical pediatric neurology: a signs and symptoms approach. 7th ed. London: Elsevier Saunders;2013.
|
32 |
Dubowitz V. Muscle disorders in childhood. 2nd ed. London: Bailliere Tindall; 1995.
|
33 |
North KN, Wang CH, Clarke N, Jungbluth H, Vainzof M, Dowing JJ, et al. Approach to the diagnosis of congenital myopathies. Neuromuscl Dis 2014;24:97-116.
DOI
|
34 |
Dowling JJ, Gonorazky HD, Cohn RD, Campbell C. Treating pediatric neuromuscular disorders: the future is now. Am J Med Genet A 2018; 176:804-41.
DOI
|
35 |
Darras BT, Jones HR. Diagnosis of pediatric neuromuscular disorders in the era of DNA analysis. Pediatr Neurol 2000;23:289-300.
DOI
|
36 |
Sumner CJ, Paushkin S, Ko CP. Spinal muscular atrophy: disease mechanisms and therapy. San Diego: Academic Press; 2016.
|
37 |
Ravenscroft G, Davis MR, Lamont P, Forrest A, Laing NG. New era in genetics of early-onset muscle disease: breakthroughs and challenges. Semin Cell Dev Biol 2017;64:160-70.
DOI
|
38 |
Emery AE, Muntoni F, Quinlivan R. Duchenne muscular dystrophy. 4th ed. Oxford: Oxford University Press; 2015.
|